LONDON, June 14, 2016 /PRNewswire/ --

This press release is intended for UK medical media only.

Novo Nordisk today announced the full results from the LEADER trial, showing that the GLP-1 receptor analogue Victoza^® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), in addition to standard of care in 9,340 adults with type 2 diabetes at high CV risk. The main results of the LEADER trial were presented today at the American Diabetes Association's 76th Scientific Sessions (ADA 2016) and also published in the New England Journal of Medicine.^[1],[2] Victoza^® is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV events vs placebo, both in addition to standard of care, in a cardiovascular outcomes trial.

There was a significant 22% reduction in cardiovascular death with Victoza® treatment vs placebo (95% CI: 0.66; 0.93, p=0.007) and reductions in non-fatal myocardial infarction (HR=0.88, 95% CI: 0.75; 1.03, p=0.11) and non-fatal stroke (HR=0.89, 95% CI: 0.72; 1.11, p=0.30).^[1],[2]

"Liraglutide is the first GLP-1 therapy that has been shown to significantly reduce the risk of major CV events and represents great progress in our understanding of liraglutide's clinical profile," commented Professor Steve Bain, UK LEADER trial National Leader and Assistant Medical Director for Research & Development for ABM University Health Board and Clinical Lead for the Diabetes Research Unit, Wales. "Given the important link between diabetes and CV complications, it is important to be able to trust that any diabetes treatment prescribed does not add to that risk. The study findings for liraglutide have surpassed our expectations in providing us with a tool that can effectively help to treat patients' type 2 diabetes and control blood sugar levels, with the additional reassurance of reducing CV risk."

All-cause death was significantly reduced by 15% with Victoza^® compared to placebo (95% CI: 0.74; 0.97, p=0.02). The expanded CV endpoint was significantly reduced by 12% with Victoza^® compared to placebo (95% CI: 0.81; 0.96, p=0.005). The expanded CV endpoint included the three components of the primary endpoint in addition to unstable angina leading to hospitalisation, coronary revascularisation and hospitalisation for heart failure.^[1],[2]

From a mean baseline of 8.7% (both groups), there was a greater reduction in HbA1c with Victoza^® vs placebo, in addition to standard of care, at three years (estimated treatment difference [ETD]: -0.40%, 95% CI: -0.45; -0.34). Weight loss was also sustained over three years with Victoza^® treatment vs placebo (ETD: -2.3 kg, 95% CI: - 2.5; -2.0). Mean baseline weight was 91.9 kg and 91.6 kg, respectively.^[1],[2]

"We are very excited by the LEADER trial results that demonstrate a significant reduction in major cardiovascular events among type 2 diabetes patients treated with Victoza^®, including all-cause death," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "For us, this marks the beginning of a new era where our R&D focus will go beyond glucose control."

The proportion of adults experiencing adverse events was similar between the Victoza^® and the placebo groups (62.3% vs 60.8%, respectively). The most common adverse events leading to the discontinuation of Victoza^® were gastrointestinal events. The incidence of pancreatitis was non-significantly lower in the Victoza^® group than in the placebo group.^[1],[2]

 

NOTES TO EDITORS  

About LEADER 

LEADER was a multicentre, international, randomised, double-blind, placebo-controlled trial investigating the long-term effects of Victoza^® (liraglutide) up to 1.8 mg compared to placebo, both in addition to standard of care, in people with type 2 diabetes at high risk of major cardiovascular events. Standard of care was defined as lifestyle modifications, selective glucose lowering treatments and cardiovascular medications.

LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries that were followed for 3.5-5 years. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.^[1]

About Victoza^®  

Victoza^® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1.

Liraglutide was launched in the EU in 2009 and is commercially available in more than 80 countries with more than 3 million patient years of use in people with type 2 diabetes globally. In the UK, liraglutide is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.^[3]

About Novo Nordisk  

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders, and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.co.uk.  

Further information
Stephen Cull
+44-(0)-7584-447-280
scul@novonordisk.com

Rupal Patel
+44-(0)-7870-678-084
rupal.patel@packerforbes.com

Jade McCudden
+44-(0)-7424-410-749
jade.mccudden@packerforbes.com

References  

1. Results of the liraglutide effect and action in diabetes - evaluation of cardiovascular outcome results (LEADER) trial. Symposium 3-CT-SY24 at the 76th Scientific Sessions of the American Diabetes Association (ADA). 13 June 2016.

2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016; In Press. DOI: 10.1056/NEJMoa1603827.

3. EMC. Victoza® UK summary of product characteristics. April 2016. Available at: https://www.medicines.org.uk/emc/medicine/21986#INDICATIONS . Last accessed: 13 June 2016.

UK/LE/0616/0003.
Date of preparation: June 2016

SOURCE Novo Nordisk